A new clinical trial is underway in Sydney to determine if semaglutide, a medication currently used for type 2 diabetes, can improve heart health in individuals with type 1 diabetes (T1D). The trial, named REducing Cardiometabolic Risk with SEmaglutide in Type 1 diabetes (RESET1), is actively recruiting adults to participate.
People with T1D face an elevated risk of developing heart disease, a common long-term complication. Treatments that address factors contributing to poor heart health, such as excess weight, insulin resistance, and elevated blood glucose levels, are critically needed.
RESET1 Study Details
The RESET1 study is looking for 60 adults aged 25 to 70 years who meet the following criteria:
- Have a body mass index (BMI) above 25
- Have risk factors for heart disease (such as high blood pressure, high cholesterol, or are a smoker)
- Were diagnosed with T1D at least 2 years ago
Participants will be administered either semaglutide or a placebo once a week for 26 weeks. The study will involve blood and urine tests, body composition and liver scans, conducted at the Garvan Institute of Medical Research in Darlinghurst, Sydney.
Researchers will assess whether semaglutide can improve markers of heart health, alongside metabolic measures including weight, insulin sensitivity, insulin usage, and time in range.
Benefits of Participation
Participants will gain insights into their metabolism and receive test results, including body composition and energy expenditure measurements. Participation will contribute to advancing T1D research, potentially leading to improved treatments and quality of life for individuals with the condition. There is no cost to participate.
JDRF's Role
JDRF Australia has funded Dr. Jennifer Snaith, a lead researcher in the trial, through the Rebecca Davies Fellowship. This fellowship supports clinicians in conducting T1D research alongside their clinical work.
According to Dr. Snaith, the JDRF Rebecca Davies Fellowship enables the RESET1 study, which will investigate how a once-a-week injection, in addition to insulin, can address cardiovascular disease in type 1 diabetes. "The overall mission of my career and my team is to improve the lives of people living with type 1 diabetes by addressing cardiovascular health. This fellowship helps us greatly in achieving this goal."
For more information about the trial, contact RESET1@garvan.org.au or call Dr. Ruth Frampton on 0491 731 769.
